Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes by binding to the L-type calcium channels, leading to coronary vasodilation, decreased myocardial contractility, and slowed AV nodal conduction.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of hypertension,Management of angina pectoris (chronic stable, vasospastic, unstable),Rate control in atrial fibrillation/flutter,Supraventricular tachyarrhythmias
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous continuous infusion: 5-15 mg/hour (0.25-0.33 mg/kg per hour).
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
3-4.5 hours; prolonged in hepatic impairment (up to 10 hours) and in elderly
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Extensively metabolized in the liver via CYP3A4; undergoes deacetylation, N-demethylation, and O-demethylation; metabolites include desacetyl-diltiazem (active).
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: 2-4% unchanged; hepatic metabolism with biliary excretion; fecal elimination accounts for ~10%
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
70-80% bound to albumin
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
5-8 L/kg; indicates extensive tissue binding
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral: ~40-50% due to first-pass metabolism; IV: 100%
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No adjustment required for GFR >10 m L/min; for GFR <10 m L/min, use with caution and monitor heart rate.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh Class A: reduce dose to 5-10 mg/hour; Child-Pugh Class B: reduce to 2.5-5 mg/hour; Child-Pugh Class C: avoid use.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Children: 0.25-0.33 mg/kg/hour continuous IV infusion; maximum 15 mg/hour.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly: initial dose at lower end of range (5-10 mg/hour); titrate slowly due to increased sensitivity and risk of bradycardia.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
There is no FDA black box warning for diltiazem.
None.
May cause bradycardia and AV block,Concomitant use with beta-blockers increases risk of bradycardia/heart failure,Avoid in patients with left ventricular dysfunction,May worsen heart failure in patients with reduced ejection fraction,Hepatic impairment requires dose adjustment,Monitor renal function in elderly; may cause hypotension,Avoid abrupt withdrawal
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Sick sinus syndrome (except with pacemaker),Second- or third-degree AV block (except with pacemaker),Severe hypotension (systolic <90 mm Hg),Acute myocardial infarction with pulmonary congestion,Hypersensitivity to diltiazem,Concurrent use with ivabradine
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid consumption of grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing diltiazem serum concentrations and risk of toxicity. No other significant food interactions.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No adequate studies in pregnant women. In animal studies, diltiazem has been associated with embryofetal toxicity (skeletal abnormalities, increased mortality) at doses >5 times the maximum recommended human dose. Use only if potential benefit justifies risk. First trimester: potential teratogen, avoid unless essential. Second and third trimesters: may cause uterine hypoperfusion and fetal hypoxia due to maternal hypotension; monitor fetal heart rate and uterine activity if used near term.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Diltiazem is excreted into human milk; milk-to-plasma ratio approximately 0.9. Limited data suggest low levels but potential for adverse effects in nursing infants (bradycardia, hypotension). Consider alternatives, especially while nursing a preterm or low-birth-weight infant. If used, monitor infant for signs of bradycardia and hypotension.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance. No established dose adjustment guidelines; use lowest effective dose. Monitor clinical response and titrate cautiously. Consider starting at lower-end doses (e.g., 30 mg PO QID) and increase based on BP and HR. IV use may require more careful titration due to volume changes.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Diltiazem hydrochloride in 0.72% sodium chloride is an intravenous calcium channel blocker used for rate control in atrial fibrillation/flutter and hypertension. Monitor heart rate and blood pressure closely; may cause bradycardia, hypotension, and heart block. Avoid in patients with sick sinus syndrome or second/third-degree AV block without a pacemaker. The 0.72% sodium chloride concentration provides isotonicity; ensure proper IV access to prevent extravasation tissue necrosis. Contraindicated with concurrent beta-blocker use due to additive bradycardic effects.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously to control heart rate or lower blood pressure.,You will have your heart rate and blood pressure monitored continuously during infusion.,Report symptoms of dizziness, fainting, slow heart rate, or difficulty breathing.,Avoid grapefruit juice as it may increase drug levels and side effects.,Do not stop taking other heart medications without consulting your doctor.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Mebendazole, an anthelmintic, inhibits CYP3A4-mediated metabolism of diltiazem, a calcium channel blocker used for hypertension and angina. This results in elevated diltiazem plasma concentrations, increasing the risk of bradycardia, hypotension, and atrioventricular block. Patients may experience enhanced negative chronotropic effects, leading to symptomatic bradycardia or heart block."
"Antipyrine, a substrate of cytochrome P450 (CYP) 3A4, when coadministered with Diltiazem, a moderate inhibitor of CYP3A4, results in decreased metabolic clearance of Diltiazem. This leads to increased plasma concentrations of Diltiazem, potentiating its negative chronotropic and hypotensive effects. Clinically, this interaction may manifest as bradycardia, atrioventricular block, and excessive hypotension."
"Diltiazem, a moderate CYP3A4 inhibitor, can significantly increase the systemic exposure of ceritinib, a sensitive CYP3A4 substrate. This interaction leads to elevated ceritinib plasma concentrations, potentiating its dose-dependent toxicities, including hepatotoxicity, QT interval prolongation, and gastrointestinal disturbances. Concomitant use may require ceritinib dose reduction or temporary discontinuation to mitigate adverse effects."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is a Electrolyte that works by Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes by binding to the L-type calcium channels, leading to coronary vasodilation, decreased myocardial contractility, and slowed AV nodal conduction.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is: Intravenous continuous infusion: 5-15 mg/hour (0.25-0.33 mg/kg per hour).. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is classified as Category A/B. No adequate studies in pregnant women. In animal studies, diltiazem has been associated with embryofetal toxicity (skeletal abnormalities, increased mortality) at doses >5 times th. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.